sellWeak10b5-1 plan
Glenda Dorchak sold $48k of ANSS
director at ANSYS INC. 152 shares at an average of $313.61, traded Oct 7, 2024, filed Oct 7, 2024.
Warning score
2Value
$48k
152 shares
Holdings after
3,630
-4% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleDirector
- +7Trade size$48k at market
- 0Share of holdings soldSold 4.0% of holdings
- 0ClusterNo other insider selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001214659-24-017265, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 7, 2024 | SOpen-market sale Common Stock10b5-1 | -152 | $313.61 | $48k | 3,630 | Oct 7, 2024 |
Related signals
Other insiders at ANSYS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 2Weak | ANSYS INC | Glenda Dorchak director | $60k 200 shares | -6% | |
| 3Weak | ANSYS INC | Glenda Dorchak director | $67k 200 shares | -6% | |
| 2Weak | ANSYS INC | Glenda Dorchak director | $53k 159 shares | -4% | |
| 2Weak | ANSYS INC | Glenda Dorchak director | $51k 150 shares | -5% | |
| 3Weak | ANSYS INC | Glenda Dorchak director | $69k 200 shares | -6% | |
| 15Weak | ANSYS INC | Ajei Gopal President and CEO | $2.9M 9,566 shares | -4% | |
| 20Weak | ANSYS INC | Ajei Gopal President and CEO | $9.4M 30,728 shares | -14% | |
| 40Moderate | ANSYS INC | Shane Emswiler SVP, Products | $1.2M 3,859 shares | -13% | |
| 49Moderate | ANSYS INC | Walter Hearn SVP, World Sales & Cust. Exc. | $581k 1,950 shares | -9% | |
| 44Moderate | ANSYS INC | Janet Lee SVP, GC and Secretary | $296k 984 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.